The Animal Core will provide investigators of each project with assistance in the conduct of research involving animals. The core will provide a focus of expertise that is germane to all projects and also efficiently utilize valuable resources. The core?s PI, Dr. Dysko, is an American College of Laboratory Animal Medicine certified veterinarian and Associate Director of the Unit for Laboratory Animal Medicine. Dr. Dysko will oversee the day-to-day activities of the Animal Core. Dr. Michael Cher, a consultant from Wayne State University, developed the SCID-hu animal model for prostate cancer that will be used in the projects and will provide active scientific support into the ongoing research activities of the various projects. Dr. Paul Krebsbach, a consultant from the University of Michigan, will facilitate use of the ?ossicle model? that involves implanting a sponge with stromal cells and tumor cells. The Animal Core activities include: 1. Creating animal models to be used for the projects. Implantation of fetal bone, sponges and other tissues as required to produce SCID-hu mice and other animal models will be performed by the Animal Core. 2. Assisting with animal experiments. Core personnel will coordinate and assist or instruct in the performance of standardized procedures such as animal injections, intracardiac injection, anesthesia, etc. 3. Providing expertise in use of the SCID-hu mice and ossicle models, and interpretation of data from these animals. Dr. Cher will provide input in both an informal basis and through planned progress meetings. 4. Maintaining breeding colonies for various specialized mice as required for various projects. Specific genetically modified mice will be maintained as required.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA093900-04
Application #
7421003
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-05-01
Budget End
2008-04-30
Support Year
4
Fiscal Year
2007
Total Cost
$255,913
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Jung, Younghun; Cackowski, Frank C; Yumoto, Kenji et al. (2018) CXCL12? Promotes Metastatic Castration-Resistant Prostate Cancer by Inducing Cancer Stem Cell and Neuroendocrine Phenotypes. Cancer Res 78:2026-2039
Decker, A M; Taichman, L S; D'Silva, N J et al. (2018) Periodontal Treatment in Cancer Patients: An Interdisciplinary Approach. Curr Oral Health Rep 5:7-12
Miller, Dannah R; Tzeng, Cherng-Chyi; Farmer, Trey et al. (2018) Novel CIL-102 derivatives as potential therapeutic agents for docetaxel-resistant prostate cancer. Cancer Lett 436:96-108
Machioka, Kazuaki; Izumi, Kouji; Kadono, Yoshifumi et al. (2018) Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines. Oncotarget 9:16185-16196
Hill, Elliott E; Kim, Jin Koo; Jung, Younghun et al. (2018) Integrin alpha V beta 3 targeted dendrimer-rapamycin conjugate reduces fibroblast-mediated prostate tumor progression and metastasis. J Cell Biochem 119:8074-8083
Axelrod, Haley D; Valkenburg, Kenneth C; Amend, Sarah R et al. (2018) AXL Is a Putative Tumor Suppressor and Dormancy Regulator in Prostate Cancer. Mol Cancer Res :
de Groot, Amber E; Pienta, Kenneth J (2018) Epigenetic control of macrophage polarization: implications for targeting tumor-associated macrophages. Oncotarget 9:20908-20927
Roca, Hernan; Jones, Jacqueline D; Purica, Marta C et al. (2018) Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone. J Clin Invest 128:248-266
Wu, Amy; Liao, David; Kirilin, Vlamimir et al. (2018) Cancer dormancy and criticality from a game theory perspective. Cancer Converg 2:1
Park, Sun H; Keller, Evan T; Shiozawa, Yusuke (2018) Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis. Calcif Tissue Int 102:152-162

Showing the most recent 10 out of 228 publications